Evotec OAI AG Signs Chemical Library Agreement with Merck & Co., Inc.
Under the terms of the agreement, Evotec OAI will synthesise well characterised drug-like library compounds using its proprietary high-speed combinatorial chemistry and auto-purification platforms. Merck will use these compounds in its drug research and development programs. "We believe that Evotec OAI’s proprietary technology platforms will uniquely contribute to our compound acquisition program." said Thomas N. Salzmann, Ph.D., Senior Vice President, Basic Research, Merck. “This major agreement reaffirms the value of our highly industrialised process for synthesising compound libraries,” said Mario Polywka, Chief Operating Officer of Evotec OAI.“ We are delighted to be working with Merck and contributing to their identification of high quality drug candidates through the application of our leading-edge chemistry solutions.”
Other news from the department science
These products might interest you
Milli-Q® Services / MyMilli-Q™ by Merck Life Science
Services & Support for Water Purification Systems
Quality Care, Delivered. In Person & Online
Good Weighing Practice by Mettler-Toledo
Your Concrete Weighing Quality Assurance Plan
GWP Verification service
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.